Literature DB >> 17498252

Hepatocyte senescence in end-stage chronic liver disease: a study of cyclin-dependent kinase inhibitor p21 in liver biopsies as a marker for progression to hepatocellular carcinoma.

Elizabeth M Brunt1, Sarah N Walsh, Paul H Hayashi, Jennifer Labundy, Adrian M Di Bisceglie.   

Abstract

BACKGROUND: Histologic markers to predict hepatocellular carcinoma (HCC) include small cell change and dysplastic nodules. Hepatocyte senescence is noted in chronic liver disease and may or may not be important in progression to HCC. AIM: The study was undertaken to compare standard histologic features of chronic liver disease as well as markers of senescence and proliferation in two groups of biopsies from patients followed for at least a year.
METHODS: Standard histologic evaluation of necroinflammatory activity, fibrosis, steatosis, and iron, internationally accepted criteria of dysplasia, and immunohistochemical markers for proliferation and hepatocyte senescence were compared in 47 liver biopsies from noncholestatic chronic liver disease patients who subsequently either underwent transplant (the Control group, n=19) or had biopsy-proven (HCC group, n=28) over a similar time period of 34.9 months (mean) and 42.5 months (mean) respectively.
RESULTS: Both groups were predominantly men; the MELD score was higher, and mean age was less in the Control group (46.9 vs 53.8 years, P=0.01). Small cell change was not significantly different in the biopsies between the two groups; neither were grade, stage (Ishak scores), nor presence or location of iron. Steatosis was more common in the group that subsequently developed HCC (P=0.04). The MIB-1 proliferation index was greater in the biopsies from the Control group. The senescence marker p21, and the ratio of p21:MIB-1 were not statistically different between the two groups. However, a Spearman's rank correlation showed a linear correlation of p21/MIB-1 with a greater amount of dyplasia in the explant livers of Controls.
CONCLUSIONS: These findings suggested the Control groups' livers maintained effective removal of cells from the cell cycle by overexpression of p21 and, while not 'protected' from significant involvement by dysplasia, may have been precluded from development of HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498252     DOI: 10.1111/j.1478-3231.2007.01470.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  8 in total

1.  Hepatic progenitor cell proliferation and liver injury in α-1-antitrypsin deficiency.

Authors:  Elizabeth M Brunt; Keith Blomenkamp; Muneeb Ahmed; Faiza Ali; Nancy Marcus; Jeffrey Teckman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-11       Impact factor: 2.839

2.  Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migration.

Authors:  Katharine M Irvine; Richard Skoien; Nilesh J Bokil; Michelle Melino; Gethin P Thomas; Dorothy Loo; Brian Gabrielli; Michelle M Hill; Matthew J Sweet; Andrew D Clouston; Elizabeth E Powell
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 3.  The role of telomeres and telomerase in cirrhosis and liver cancer.

Authors:  Jean-Charles Nault; Massih Ningarhari; Sandra Rebouissou; Jessica Zucman-Rossi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-06-28       Impact factor: 46.802

4.  Hepatocyte proliferation/growth arrest balance in the liver of mice during E. multilocularis infection: a coordinated 3-stage course.

Authors:  Chuanshan Zhang; Junhua Wang; Guodong Lü; Jing Li; Xiaomei Lu; Georges Mantion; Dominique A Vuitton; Hao Wen; Renyong Lin
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

5.  Genome-wide transcriptional reorganization associated with senescence-to-immortality switch during human hepatocellular carcinogenesis.

Authors:  Gokhan Yildiz; Ayca Arslan-Ergul; Sevgi Bagislar; Ozlen Konu; Haluk Yuzugullu; Ozge Gursoy-Yuzugullu; Nuri Ozturk; Cigdem Ozen; Hilal Ozdag; Esra Erdal; Sedat Karademir; Ozgul Sagol; Dilsa Mizrak; Hakan Bozkaya; Hakki Gokhan Ilk; Ozlem Ilk; Biter Bilen; Rengul Cetin-Atalay; Nejat Akar; Mehmet Ozturk
Journal:  PLoS One       Date:  2013-05-15       Impact factor: 3.240

6.  Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial.

Authors:  Laurent Spahr; Yves Chalandon; Sylvain Terraz; Vincent Kindler; Laura Rubbia-Brandt; Jean-Louis Frossard; Romain Breguet; Nicolas Lanthier; Annarita Farina; Jakob Passweg; Christoph D Becker; Antoine Hadengue
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

7.  Huperzine A attenuates nonalcoholic fatty liver disease by regulating hepatocyte senescence and apoptosis: an in vitro study.

Authors:  Xiao-Na Hu; Jiao-Feng Wang; Yi-Qin Huang; Zheng Wang; Fang-Yuan Dong; Hai-Fen Ma; Zhi-Jun Bao
Journal:  PeerJ       Date:  2018-06-26       Impact factor: 2.984

8.  The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease.

Authors:  Jing Zhang; Yanpeng Li; Bingyuan Wang; Yan Luo; Junping Shi; Baiyun Zhao
Journal:  Med Sci Monit       Date:  2020-03-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.